Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer

About half of the patients treated with docetaxel in the setting of metastatic castration-resistant prostate cancer (CRPC) are non-responders. Therefore, a marker of response would be beneficial for clinical decision-making. We evaluated class III β-tubulin (βIII-tubulin) expression as a predictor o...

Descripción completa

Detalles Bibliográficos
Autores principales: Maahs, Lucas, Sanchez, Bertha E., Gupta, Nilesh, Van Harn, Meredith, Barrack, Evelyn R., Reddy, Prem-veer, Hwang, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816559/
https://www.ncbi.nlm.nih.gov/pubmed/31658275
http://dx.doi.org/10.1371/journal.pone.0222510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816559/
https://www.ncbi.nlm.nih.gov/pubmed/31658275
http://dx.doi.org/10.1371/journal.pone.0222510

Ejemplares similares